M
Modiblast develops a novel in vivo cell reprogramming approach to treat hematological malignancies and other cancers. This proprietary strategy aims to trigger innate and adaptive immune responses and establish memory cells against tumors. The company is advancing a lead program for acute myeloid leukemia (AML) with a focus on creating a self-administrable maintenance therapy.
Updated 2 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- Modiblast develops a novel in vivo cell reprogramming approach to treat hematological malignancies and other cancers. This proprietary strategy aims to trigger innate and adaptive immune responses and establish memory cells against tumors. The company is advancing a lead program for acute myeloid leukemia (AML) with a focus on creating a self-administrable maintenance therapy.